Foghorn Therapeutics is a biopharmaceutical company that specializes in creating medicines targeting genetically determined dependencies within the chromatin regulatory system. Its Gene Traffic Control platform allows the company to develop small molecule inhibitors for the treatment of relapsed and refractory acute myeloid leukemia and myelodysplastic syndrome, as well as developing protein degraders treatments for those with synovial sarcoma. Through research collaborations and license agreements with companies like Merck Sharp & Dohme, Foghorn Therapeutics aims to discover and create novel oncology medicines.